NervGen Pharma Corp. NGEN
1.90 USD -0.06 (-3.06%)
Regular-session close
1.96 +0.06 +3.16%
Pre-market · Nov 19, 4:00 AM ET
1.84 Day range 2.08
1.28 52-week range 6.30
- YTD
- -66.07%
- 1 year
- -27.20%
News
globenewswire.com NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)…benzinga.com NervGen Pharma Q3 EPS $(0.04) Beats $(0.12) Estimate NervGen Pharma (NASDAQ:NGEN) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.12) by 66.67 percent.
globenewswire.com NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)…benzinga.com NervGen Says FDA Grants NVG-291 Breakthrough Therapy Designation For Treatment Of Chronic Traumatic Cervical Motor-Incomplete SCI Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI studyPhase 3 RESTORE registrational study enrolling…
globenewswire.com NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)…
